Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. is positioned for positive financial momentum as its novel treatment model demonstrates the ability to drive faster adoption and higher case starts, which is likely to enhance revenue growth with minimal additional investment. The company has observed promising patient outcomes, with significant percentages showing improvement in obstructive sleep apnea (OSA) symptoms, suggesting a strong potential for market penetration, particularly in North America and rapidly growing regions like Asia Pacific. Furthermore, the sequential revenue growth in the second quarter of FY25, along with increases in sleep testing and sponsorship revenues, indicates a resilient financial foundation despite rising operating expenses.

Vivos Therapeutics Inc has experienced a Year-over-Year revenue decline of 9% in the first half of 2025, primarily due to its transition to a new sleep center operation model which has led to a drop in revenues by 6% in Q2 compared to the same period last year. The company also reported a deterioration in gross margins, falling to 55% due to discounting and a shift in the mix of products and services offered, further contributing to financial instability. Risks such as lower-than-expected sales growth from increased competition, potential regulatory challenges, and difficulties in acquiring new customers or penetrating additional markets heighten the negative outlook on the company's financial prospects.